PARP Inhibitors Prolong Survival in Triple-Negative Breast Cancer

As Reported by Bloomberg.com. 2009 May 31

A PARP inhibitor, a new type of drug being used in breast cancer, extended survival by more than 60% in patients with triple-negative disease. Investigators tout the PARP inhibitors as a new breakthrough in breast cancer treatment that may receive approval...

NOT A MEMBER?

OncologySTAT registration is FREE and takes less than a minute to complete. Registration provides instant access to 100+ Elsevier cancer-related journals, journal scans, daily medical and regulatory news, professional drug and interactions databases, chemotherapy regimens, and InfoBLAST - OncologySTAT's weekly e-newsletter.

 

Follow OncologySTAT on Twitter

Look for news reports from ASCO and other major conferences, journal scans, and more.
Start following ›

Sign up for our newsletters

Too busy to follow cancer's top stories? Sign-up for 1 or more of our free newsletters -- delivered weekly to your inbox.
Sign-up now  ›

Cancer Types Spotlight

more types
close
  • Bladder
  • Bone
  • Breast
  • Breast (ER Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • HIV-Related Cancers
  • Bladder
  • Bone
  • Breast
  • Breast (ER Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • HIV-Related Cancers
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin (Melanoma)
  • Skin (Non-Melanoma)
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
    • Forgot your password?
    Not a member? Free registration